For most community oncology practices, infused drugs are both the largest expense and the largest share of revenue. How those drugs reach the chair, and who bills for them, shapes cash flow more than almost any other operational decision. Under buy-and-bill, the practice buys the drug, stores it, administers it, and bills the payer for both the drug and the infusion. Under white bagging, a payer-designated specialty pharmacy dispenses a patient-specific dose and ships it to the practice, and the pharmacy bills the drug. Teams that rely on dedicated chemotherapy billing services see the difference immediately on the claim, in the remittance, and in the margin. This guide compares the two models, explains how claims are built under each, and shows where practices lose money when a payer shifts drugs from one model to the other.
How Each Model Works
Buy-and-Bill
In buy-and-bill, the practice purchases drugs from a wholesaler or specialty distributor, usually through a group purchasing organization. The drug sits in the practice's pharmacy until it is prepared and administered. The practice then submits a claim under the patient's medical benefit with two kinds of lines: the drug, reported with a HCPCS J-code and the National Drug Code (NDC), and the administration, reported with CPT codes such as 96413 for the first hour of chemotherapy infusion and 96415 for each additional hour.
The practice carries the risk. It pays the distributor on terms, often 30 to 60 days, and hopes the payer reimburses before the invoice is due and for more than the acquisition cost.
White Bagging
In white bagging, the payer requires the drug to be dispensed by a specialty pharmacy, often one affiliated with the payer or its pharmacy benefit manager. The pharmacy receives the order, verifies benefits, dispenses a dose labeled for a specific patient, and ships it to the practice. The pharmacy bills the drug, usually under the pharmacy benefit. The practice bills only the administration and related services.
Brown Bagging and Clear Bagging
Two related terms come up in payer conversations. Brown bagging means the drug is shipped to the patient, who brings it to the practice, which raises storage and chain-of-custody concerns for hazardous or temperature-sensitive drugs. Clear bagging generally refers to a drug dispensed by a health system's own specialty pharmacy. Most oncology practices are dealing with white bagging mandates rather than these variations.
Where the Revenue Difference Comes From
The financial gap between the two models comes from the drug line. Under buy-and-bill, the practice is paid for the drug at a contracted rate. For traditional Medicare Part B, most separately payable drugs are paid at average sales price (ASP) plus 6 percent, before sequestration, and CMS publishes the updated payment limits every quarter in its Medicare Part B drug ASP pricing files. Commercial contracts are often written as a percentage of ASP or wholesale acquisition cost.
The difference between what the practice paid for the drug and what the payer reimburses is the drug margin. That margin is not pure profit. It funds pharmacy staff, storage, compounding equipment, inventory carrying costs, bad debt on patient cost-sharing, and the administrative work of prior authorizations and claim follow-up. Administration codes alone usually do not cover the full cost of running an infusion suite.
When a drug is white bagged, that drug line disappears from the practice's claim. The practice keeps the administration revenue but loses the margin, while most of its infusion costs remain.
A Simplified Example
Consider an illustrative monoclonal antibody infusion. The numbers below are hypothetical and are only meant to show the structure of the comparison:
- Drug acquisition cost to the practice: $4,800
- Drug reimbursement under the practice's contract: $5,100
- Administration reimbursement for the infusion codes: $260
Under buy-and-bill, the practice collects $5,360 and nets $560 before overhead. Under white bagging, the practice collects only the $260 administration payment. The pharmacy, staff time, chair time, and nurse monitoring are largely the same in both cases. Multiply that gap across hundreds of infusions a month and the effect on practice revenue becomes clear.
How Claims Differ Under Each Model
Buy-and-Bill Claim Components
- HCPCS drug code with the correct units based on the billing unit in the code descriptor
- NDC in the required format with the NDC unit of measure and quantity
- Administration codes with the correct hierarchy, such as 96413, 96415, 96417, and 96367 for sequential hydration or supportive drugs
- JW modifier for discarded drug from a single-dose container when required, and JZ when no amount was discarded, for Medicare and payers that follow the same policy
- Diagnosis codes that meet the payer's coverage policy for the drug
White Bagging Claim Components
- Administration codes only, with the same hierarchy rules
- No drug line billed by the practice in most cases, because the pharmacy bills the drug
- Some payers ask practices to report the drug HCPCS code with a nominal or zero charge for tracking purposes, so the payer's policy should be checked before submission
A common error after a payer switches a drug to white bagging is billing the drug line anyway. The payer denies it, or worse, pays it and later recoups the payment as a duplicate of the pharmacy claim. The reverse also happens: a practice assumes a drug is white bagged, never bills it, and later realizes the drug was purchased through its own inventory.
Operational Risks That Affect Revenue
Dose Changes on Treatment Day
Oncology doses change often. Lab results, weight changes, or toxicities can lead the oncologist to reduce or hold a dose on the day of treatment. Under buy-and-bill, the pharmacy adjusts the dose from stock. Under white bagging, the dispensed dose is patient-specific and fixed. If the dose changes, the practice may have to delay treatment until a new dose arrives, which means a lost chair slot and a rescheduled patient.
Waste and Unusable Drug
A white-bagged drug labeled for one patient cannot be used for another. If the patient's treatment is stopped or changed, the drug is often wasted. The practice usually cannot bill for it, and depending on state pharmacy rules, may not be able to return it.
Chain of Custody and Storage
The practice is still responsible for receiving, storing, and preparing the drug safely. That includes temperature monitoring, hazardous drug handling, and documentation, without any drug revenue to support it.
Administrative Burden
White bagging adds steps: coordinating orders with an outside pharmacy, tracking shipments, confirming arrival before scheduling, and handling separate prior authorization requirements on the pharmacy benefit. Each step adds staff time that the administration fee does not fully cover.
Patient Cost-Sharing Under Each Model
The billing model also changes what the patient owes and who collects it. Under buy-and-bill, the drug falls under the medical benefit, so the patient's deductible and coinsurance apply to the drug line on the practice's claim. The practice is responsible for collecting that balance, which can be large for high-cost biologics, and for helping patients apply for manufacturer assistance or foundation support.
Under white bagging, the drug is often billed under the pharmacy benefit, which can have a different deductible, a specialty tier copay, or coinsurance tied to the pharmacy plan. Patients may receive a bill from the specialty pharmacy that they did not expect, and some pharmacies will not ship until the patient's cost-sharing is resolved. That can delay treatment even when the practice is ready to infuse.
Financial counselors should explain to patients which benefit covers their drug, who will bill them, and what assistance programs apply. Recording this in the patient's account before the first infusion reduces confusion, missed treatments, and bad debt on the practice side.
Coordinating Assistance Programs
Manufacturer copay programs and foundation grants usually have separate enrollment for medical and pharmacy benefits. When a payer moves a drug to white bagging mid-treatment, a patient's existing assistance enrollment may no longer apply. Checking assistance status whenever the distribution model changes keeps patients from receiving surprise balances.
What Practices Can Do
Know Which Payers and Drugs Are Affected
Keep a current list of payer site-of-care and specialty pharmacy policies, organized by drug. Payers often update these lists quarterly, and a change that goes unnoticed can produce weeks of denied drug lines.
Build Payer-Specific Order Workflows
At the time of scheduling, the authorization team should confirm whether the drug will be bought and billed or dispensed by a specialty pharmacy. That decision should flow into the pharmacy order, the charge capture template, and the claim, so the billing team knows whether a drug line belongs on the claim.
Track the Financial Impact
Measure white bagging volume by payer and drug, and estimate the lost margin. These numbers matter in contract negotiations. Some practices have successfully negotiated exceptions or higher administration rates when they can show the actual cost of mandates.
Request Exceptions When Clinically Appropriate
Many payer policies allow exceptions, for example when treatment is urgent, when doses change frequently, or when a delay could harm the patient. Documenting these situations and requesting exceptions case by case can preserve buy-and-bill for the patients where it matters most.
Review State Law
Several states have passed laws that restrict or regulate payer white bagging mandates. Practices should check whether their state limits these policies and how the law applies to fully insured versus self-funded plans, which state laws may not reach.
Audit the Revenue Cycle
Revenue cycle partners such as Med Xpert Services often run monthly reports comparing scheduled infusions, drug purchases, and billed drug lines. Any infusion with a purchased drug but no drug line, or a billed drug line for a white-bagged drug, gets flagged for review before it becomes a lost charge or a recoupment.
Common Mistakes and Fixes
- Billing the drug after a white bagging switch. Update charge templates as soon as a payer policy changes.
- Missing a drug line for a purchased drug. Reconcile pharmacy dispensing records with billed charges every week.
- Wrong drug units. Convert the administered dose to HCPCS billing units carefully, and report the NDC quantity in the correct unit of measure.
- Missing JW or JZ modifiers. Apply discarded drug reporting rules for single-dose containers on every buy-and-bill claim where they apply.
- Ignoring the administration hierarchy. Report the initial service correctly so add-on and sequential codes are paid.
- No exception requests. Track clinical situations where a white bagging exception could be justified.
Frequently Asked Questions
What is the main difference between buy-and-bill and white bagging?
Under buy-and-bill, the practice purchases the drug and bills the payer for both the drug and its administration. Under white bagging, a specialty pharmacy dispenses and bills the drug, and the practice bills only the administration.
Does Medicare require white bagging?
Traditional Medicare Part B pays practices for most physician-administered drugs under buy-and-bill, generally at ASP plus 6 percent. White bagging mandates are mainly a commercial payer and pharmacy benefit manager practice.
Can a practice bill the drug if it was white bagged?
Generally no, because the specialty pharmacy bills the drug. Billing it again can result in a denial or a later recoupment. Some payers ask for a tracking line with a nominal charge, so follow the specific payer instructions.
Why do oncology practices oppose white bagging?
Practices point to lost drug margin that supports infusion operations, treatment delays when doses change, wasted patient-specific drugs, and added administrative work.
How can a practice reduce the financial impact of white bagging?
Track affected payers and drugs, update charge capture workflows, request clinical exceptions, use data in contract negotiations, and review state laws that limit payer mandates.
Conclusion
Buy-and-bill gives oncology practices control over inventory and dose changes along with the drug margin that supports infusion care, while white bagging shifts the drug claim to a specialty pharmacy and leaves the practice with administration revenue and much of the same cost. Understanding exactly how claims differ, tracking payer mandates by drug, and reconciling purchases against charges helps protect revenue as payer policies change. For oncology groups that want consistent support with drug and infusion claims, working with experienced Medical Billing Services keeps both models billed correctly.
Comments
Post a Comment